Physician profile
Scott Rosman
NPI 1568750651
$12,696.80
in general payments reported to CMS, 2019-2025
29 companies · $2,077 in 2025
The $2,077 reported for 2025 was more than what 94% of Community Health (Nurse Practitioner) providers received nationally (typical 2025 total: $139).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $789 · 2022: $1,775 · 2023: $4,925 · 2024: $3,131 · 2025: $2,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,033 · Consulting Fee: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,032.95 |
| Consulting Fee | $2,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,005.94 | 2021-2025 | Dovato, Apretude, Rukobia |
| Abbvie INC. | $2,693.13 | 2021-2025 | |
| Gilead Sciences, INC. | $1,482.14 | 2021-2025 | Sunlenca |
| Glaxosmithkline, LLC. | $943.40 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $484.90 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $478.25 | 2021-2025 | Verquvo, Pifeltro, Delstrigo |
| Novartis Pharmaceuticals Corporation | $347.02 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $300.22 | 2023-2025 | Breztri, Farxiga, Bevespi Aerosphere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.04 | 2023-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $236.73 | 2022-2024 | |
| Abbott Laboratories | $227.57 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $177.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Biotech, INC. | $172.72 | 2021-2023 | Symtuza |
| Amgen INC. | $168.71 | 2023-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $135.00 | 2025 | Cresemba |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $108.92 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Emd Serono, INC. | $73.43 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $50.65 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $41.76 | 2024 | Eliquis |
| Daiichi Sankyo INC. | $41.67 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $40.28 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.98 | 2025 | Caplyta |
| Indivior INC. | $35.33 | 2025 | Sublocade |
| Phathom Pharmaceuticals, INC. | $34.82 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $31.25 | 2023-2024 | Invega Sustenna, Invega Trinza |
| Verona Pharma, INC. | $28.85 | 2025 | Ohtuvayre |
| Halozyme INC | $25.98 | 2023 | |
| Alkermes, INC. | $21.90 | 2025 | Vivitrol |
| Braeburn INC. | $15.03 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Rosman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.